1. President Trump readying drug pricing executive orders — Roche Tecentriq-Avastin combo fails to hit primary endpoint in ovarian cancer trial — Moderna's COVID vaccine could see $5B or more in sales, say analysts — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Please take our quick survey on how COVID-19 is impacting your job It will only take a minute or two to respond. The survey is confidential, and does not require registration. Thank you in advance for your participation. We will provide regular updates on results as responses accumulate.
    Dismiss Notice

How much longer do we have?

Discussion in 'Amgen' started by anonymous, Mar 29, 2020 at 12:23 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    have you seen their portfolio of products? Layoffs gonna happen there sooner or later. With recent events it looks like sooner.
     

  2. anonymous

    anonymous Guest

    ...just like the clock is ticking at Amgen. Our pipeline, while it looks promising is not necessarily a top 10. The company would tell otherwise to keep the reps at the company vs leaving. Keep your eyes open.
     
  3. anonymous

    anonymous Guest

    Maybe I’m missing something but are our growth brands...Prolia, Evenity, Repatha, Aimovig, etc....facing bio similar competition in the near future?

    BI was facing a recorg irregardless of corona.

    amgen may not a Humira in the pipeline but who does? The respiratory tezepelumab and the HF med look pretty promising.
     
  4. anonymous

    anonymous Guest

    Repatha is NOT a growth brand moron! Prolia arguably is. Aimovig? Please.... but the bottom line Amgen cannot keep paying us to do nothing! That’s the reality! Pfizer also looking at trimming. The days when the wheels came off is now. Sucks but it’s the reality!
     
  5. anonymous

    anonymous Guest

    What is wrong with you? One company out of hundreds is asking people to take vacation during some of this time is not the same as a layoff - it's a bad move on S/A's part for sure, but it is not a layoff - if that is even true and not a rumor. BI, also is not a layoff. They confirmed that all jobs are safe until June and then they will reevaluate...stop with your doomsday nonsense.
     
  6. anonymous

    anonymous Guest

    you sir are very very naive
     
  7. anonymous

    anonymous Guest

    Im not pulling this out of thin air. I’m going off the Q4 and 2019 financial performance. Go see for yourself. Double digit growth for following brands: Prolia, Parsabiv, Blyncito, Nplate, Vectibix, and wait for it............Aimovig, and Repatha (yes....double digit growth by dollars even after discounting 60%). Didn’t even mention Evenity....launched so late in the year they didn’t include I’m thinking.

    Hell....even Enbrel grew (not by double digits) in a very competitive market.

    The internet is already your friend based on your presence here. Try using it to look at Q4 and 2019 performance. Based on what I’m hearing Q1 shaping up nicely for these brands as well. Expanding the market with new writers and new buy and bill contacts don’t spontaneously happen. They need us to make up for biosimilar uptake taking business from Neulasta, Neupogen, Epogen, etc....

    But if doom and gloom is your thing....go right on ahead.
     
  8. anonymous

    anonymous Guest

    Of the now 27 posts here all but 3 are the same person. I was an English major in college and writing style is the same! It’s hilarious to see the same person on CP arguing with himself! Keep it going!
     
  9. anonymous

    anonymous Guest

    I am not worries about Q1. I am more worried about Q2 and Q3. The growth will be negative in all brands listed. If the ship is not righted quickly the sales force will be reduced.
     
  10. anonymous

    anonymous Guest

    So move on with your life then